Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial-Reference-Cited by-同舟云学术

Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial

Published:2023-03 Issue:3 Volume:8 Page:215-227
ISSN:2468-1253
Container-title:The Lancet Gastroenterology & Hepatology
language:en
Short-container-title:The Lancet Gastroenterology & Hepatology

Author:

Louis Edouard,Resche-Rigon Matthieu,Laharie David,Satsangi Jack,Ding Nik,Siegmund Britta,D'Haens Geert,Picon Laurence,Bossuyt Peter,Vuitton Lucine,Irving Peter,Viennot Stephanie,Lamb Christopher A,Pollok Richard,Baert Filip,Nachury Maria,Fumery Mathurin,Gilletta Cyrielle,Almer Sven,Ben-Horin Shomron,Bouhnik Yoram,Colombel Jean-Frederic,Hertervig Erik,Andrews Jane,Sparrow Miles,Leong Rupert,Connor Susan,Radforth-Smith Graham,De Cruz Peter,Preiss Jan,Stallmach Andrea,Liceni Thomas,Grip Olaf,Halfvarson Jonas,Durai Dharmaraj,Cummings Fraser,Seilinger Christian,Parkes Miles,Lindsay James,Lambrecht Guy,Van Hootegem Philippe,Rahier Jean-François,Dewitte Marie,Hebuterne Xavier,Chanteloup Elise,Altwegg Romain,Nancey Stephane,Bouguen Guillaume,Pineton de Chambrun Guillaume,Poullenot Floriant,Roblin Xavier

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference30 articles.

1. Crohn's disease;Torres;Lancet,2017

2. STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD;Turner;Gastroenterology,2021

3. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial;Colombel;Lancet,2017

4. Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial;Khanna;Lancet,2015

5. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease;Rutgeerts;Gastroenterology,1999

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comment on: Long-term effectiveness and safety of anti-TNF in pediatric-onset inflammatory bowel diseases: A population-based study;Digestive and Liver Disease;2024-09

2. Malignancy, a real risk in patients using anti-TNF drugs for Crohn’s disease?;Journal of Case Reports and Images in Pathology;2024-08-29

3. External validation of serum biomarkers predicting short-term and mid/long-term relapse in patients with Crohn’s disease stopping infliximab;Gut;2024-08-12

4. Evaluating the Efficacy of Infliximab in Inflammatory Bowel Disease: A Systematic Review of the Literature;Cureus;2024-08-01

5. De-escalating therapy in inflammatory bowel disease: Results from an observational study in clinical practice;Gastroenterología y Hepatología (English Edition);2024-08